Changing therapy from Glivec® to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: Two case reports

Cases Journal

Volumn 2, Issue 12, 2009, Pages

  Asfour, Inas A ^a   Elshazly, Shereen A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BLAST CELL CRISIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EGYPT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; RELAPSE; SIDE EFFECT; STOMACH EROSION; TREATMENT OUTCOME;

EID: 77953378278     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-9342     Document Type: Article

References (8)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 1999, 341(3):164-172.
2. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999, 340(17):1330-1340.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
5. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology™: Chronic Myelogenous Leukemia. Version 2 2009 [http://www.nccn.org/professionals/physician-gls/f-guidelines.asp]. Requires free registration
6. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108(6):1809-1820.
7. O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz MR, Filian J, Gathmann I, Druker BJ, Larson RA: International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM) [abstract]. Blood 2008, 112(11):186.
8. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, GMALL Study Group: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109(10):2068-2076.